Celcuity (NASDAQ:CELC) released its earnings results on Thursday. The company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.03, Morningstar.com reports.
Shares of CELC traded up $0.31 during trading hours on Friday, hitting $20.11. 1,485 shares of the company were exchanged, compared to its average volume of 5,271. The stock has a market capitalization of $202.14 million, a P/E ratio of -27.18 and a beta of 0.55. Celcuity has a fifty-two week low of $18.31 and a fifty-two week high of $31.00. The company has a current ratio of 26.94, a quick ratio of 26.94 and a debt-to-equity ratio of 0.01. The business’s fifty day simple moving average is $22.24.
A number of large investors have recently added to or reduced their stakes in the stock. Northern Trust Corp boosted its stake in Celcuity by 2.0% in the fourth quarter. Northern Trust Corp now owns 61,888 shares of the company’s stock valued at $1,484,000 after buying an additional 1,223 shares in the last quarter. Geode Capital Management LLC boosted its stake in Celcuity by 9.1% in the fourth quarter. Geode Capital Management LLC now owns 35,035 shares of the company’s stock valued at $840,000 after buying an additional 2,930 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Celcuity by 9.8% in the second quarter. Charles Schwab Investment Management Inc. now owns 14,709 shares of the company’s stock valued at $368,000 after buying an additional 1,309 shares in the last quarter. Kessler Investment Group LLC boosted its stake in Celcuity by 46.3% in the first quarter. Kessler Investment Group LLC now owns 7,017 shares of the company’s stock valued at $154,000 after buying an additional 2,222 shares in the last quarter. Finally, Nelson Roberts Investment Advisors LLC acquired a new stake in Celcuity in the first quarter valued at about $115,000. 22.04% of the stock is currently owned by institutional investors and hedge funds.
Several analysts have recently issued reports on CELC shares. ValuEngine lowered Celcuity from a “buy” rating to a “hold” rating in a report on Wednesday, May 8th. Zacks Investment Research lowered Celcuity from a “buy” rating to a “hold” rating in a report on Friday. Finally, HC Wainwright set a $36.00 target price on Celcuity and gave the stock a “buy” rating in a report on Wednesday, May 8th.
Celcuity Inc, a cellular analysis company, discovers cancer sub-types and commercializes diagnostic tests to enhance the clinical outcomes of cancer patients treated with targeted therapies in the United States. The company's CELx diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it.
Recommended Story: What is the NASDAQ?
Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.